Researchers at Oregon Health and Science University have uncovered diagnostic markers and druggable driver mutations in chronic neutrophilic leukemia and atypical chronic myeloid leukemia.

The mutations indicated two different drugs that have approval for other leukemias, and already one CNL patient has been treated and showed clinical response to the drug. The researchers are now in the process of designing a clinical trial to test its efficacy in patients with CNL and atypical CML.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.